Up for the challenge
This article was originally published in SRA
Aginus Kalis, head of the Dutch Medicines Evaluation Board and chair of the management group of the EU Heads of Medicines Agencies, tells Maureen Kenny about the challenges involved in implementing the new EU pharmacovigilance legislation, especially in view of the fact that no extra funding is available.
You may also be interested in...
There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.
The UK Thalassaemia Society says that HTA body NICE fails to properly incorporate patient experiences into its decision making and that its patient engagement processes need reform. The marketing of Zynteglo, the gene therapy from bluebird bio for which the group is advocating, has just been temporarily suspended.
Bristol Myers Squibb says it is common for cell and gene therapies to revert to the standard timetable as ide-cel follows liso-cel in losing its accelerated assessment status at the European Medicines Agency. Separately, the company has discontinued development of orva-cel, a CAR-T cell therapy that was earlier in the development pipeline.